Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: gg cox who wrote (26)	8/21/2003 10:35:27 AM
From: gg cox	Read Replies (1) \| Respond to of 66

biz.yahoo.com IMI announces acceptances of pivotal paper and presentation Thursday August 21, 8:30 am ET Publication in Atherosclerosis, presentation at American Heart Association TORONTO, Aug. 21 /CNW/ - Predictive medicine company IMI International Medical Innovations Inc. (TSX:IMI - News) announced today that it has received peer- review acceptances on two of its skin cholesterol studies. This fall, a paper on IMI's pivotal study on the Cholesterol 1,2,3(TM) test will be published in the medical journal Atherosclerosis, and new data from a major U.S. study with Cholesterol 1,2,3 will be presented at the American Heart Association (AHA) annual meeting. The paper to be published in the journal Atherosclerosis is titled, "Skin tissue cholesterol is related to angiographically defined cardiovascular disease." Dr. Dennis Sprecher of The Cleveland Clinic led the multi-site study and is the lead author of the paper. The paper provides a detailed analysis of the findings of IMI's pivotal angiography study, which formed the basis of IMI's submissions to regulatory authorities and subsequent clearances. Reporting on more than 600 subjects, it will be the largest study ever published on Cholesterol 1,2,3. The abstract accepted for presentation at the American Heart Association annual meeting in November in Orlando is titled, "Non-invasive skin cholesterol measurement correlates with the presence and extent of coronary calcium." Dr. Pamela Ouyang of Johns Hopkins Medical Institutions will present the new findings, which are the first data on Cholesterol 1,2,3 from the MESA study (Multi-Ethnic Study of Atherosclerosis), led by the National Heart, Lung and Blood Institute. Cholesterol 1,2,3(TM) is the world's only non-invasive test system for cholesterol. The test measures cholesterol in the skin, by placing two drops of liquid on the palm of the hand and generating a color-change reaction. As cholesterol accumulates on artery walls it also accumulates in other tissues, including skin. High levels of skin cholesterol correlate with higher incidence of coronary artery disease. "Skin cholesterol testing is new and the case for using it needs to be made over and over again by well-respected thought leaders. Every publication and presentation is an opportunity to educate and inform the medical community," said Dr. Brent Norton, IMI President and CEO. "With a growing list of published articles and scientific presentations, combined with more than 20 current and planned studies, our clinical program is absolutely the key to realizing our cardiovascular vision, and it's never been as strong as it is today." About IMI IMI is a world leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases, particularly cardiovascular disease and cancer. The company's head office is located in Toronto, and its research and product development facility is at McMaster University in Hamilton, Ontario. For further information, please visit the company's web site at www.imimedical.com. This release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward-looking statements involve risk and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly, annual and other public filings. For further information Andrew Weir, Director, Communications, (416) 222-3449, aweir@imimedical.com